News Image

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Provided By GlobeNewswire

Last update: Mar 27, 2024

Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions

Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis

Read more at globenewswire.com

MATINAS BIOPHARMA HOLDINGS I

NYSEARCA:MTNB (7/22/2025, 8:04:00 PM)

After market: 0.98 +0.03 (+3.14%)

0.9502

-0.01 (-1.38%)



Find more stocks in the Stock Screener

Follow ChartMill for more